K-Bio Vaccine Fund 5 & 6: Investment Attraction Strategy for Bio SMEs in 2026

K-Bio Vaccine Fund: Status and Significance

The K-Bio Vaccine Fund, led by Korea's Ministry of Health and Welfare, is a dedicated policy fund for the bio-health industry. It has achieved a cumulative commitment of KRW 386.6 billion and invested KRW 95.8 billion across 20 portfolio companies. Fund 1 (KRW 150B), Fund 2 (KRW 156.6B), and Fund 4 (KRW 80B) have served as critical catalysts for the domestic biotech venture ecosystem.

Portfolio Characteristics by Fund

Fund 1: Focus on novel drug development, preference for Phase 2+ companies

Fund 2: Balanced allocation across vaccines, diagnostics, and digital health

Fund 4: Concentrated in innovative pharmaceutical companies and CDMOs

Average ticket size of KRW 4-6 billion, primarily at Series B-C stage

Fund 5 & 6 Structure (2026)

In 2026, the Ministry of Health and Welfare announced the simultaneous formation of Funds 5 and 6, each KRW 50 billion in size for a total of KRW 100 billion. Government contributes KRW 40 billion (KRW 20B per fund) as seed capital, with KRW 30 billion in private matching per fund.

Mandatory Investment Ratios

60% mandatory investment in bio-health — including drugs, devices, and digital health

10% mandatory vaccine allocation — for vaccine R&D, manufacturing, and CMO operations

Remaining 30% is at the fund manager's discretion

New fund manager selection is led by Korea Venture Investment Corp through a two-stage review

Fund Manager Requirements

VCs with proven bio-health investment track records

At least 3 specialists (medicine, pharmacy, bioengineering preferred)

Previous fund IRR of 8% or higher

Preparation for Bio SMEs

CMC, Preclinical, and Clinical Data Standards

A standardized data package by development stage is essential for due diligence.

Preclinical: GLP toxicology reports, efficacy POC data

Phase 1: PK/PD profile, primary safety endpoints

Phase 2: Interim efficacy analysis, biomarker response data

CMC: Established API process, formulation stability of 6+ months

IP Portfolio and Preferential Qualifications

Build a dual defense structure with composition-of-matter and use patents

File PCT international applications and enter national phases in US, China, and EU

Secure Innovative Pharmaceutical Company Certification for tech evaluation bonus points

Complement with Excellent Corporate Research Institute and ISO 13485 certifications

Stage-by-Stage Investment Roadmap

Seed to Series A

Technology validation and pipeline value demonstration are top priorities. Scientific rationale for the target-disease mechanism, differentiation against competing drugs, and preclinical POC for at least one pipeline are critical. Valuations typically range from KRW 10-30 billion.

Series B to C

Global expansion: FDA Pre-IND Meeting, EMA Scientific Advice outcomes

CDMO linkage: Partnerships with Samsung Biologics, Celltrion, etc.

Licensing-out discussions or MTA executions

Valuations entering the KRW 50-150 billion range

Core Pitch Deck Components

One-liner: Explain disease, target, and differentiation within 15 seconds

Unmet Need: Quantify market size and unmet demand

Science: Visualize Mechanism of Action

Pipeline & Milestones: Key events over the next 18-24 months

Financials: Burn rate, runway, use of proceeds

Complementary Strategies Beyond the Fund

A multi-track approach is more effective than relying solely on the K-Bio Fund.

TIPS: Up to KRW 500M in R&D plus Scale-up TIPS of KRW 1.5B

Korea Fund of Funds Bio Account: Year-round matching via KVIC

Regional Bio Funds: Linkages with Osong, Songdo, and Daegu bio clusters

MOHW R&D Priority: Government R&D selection recognized as private investment milestone

KITIM Consulting Services

The Korea Institute of Technology Innovation Management (KITIM) supports the entire bio-company investment journey. We provide one-stop services including investment-grade business plan and IR material advisory, Innovative Pharmaceutical Company Certification strategy, government R&D linkage planning, and technology-value-based valuation with commercialization roadmaps. Bio companies preparing for K-Bio Vaccine Fund 5 & 6 investment should [contact KITIM](/contact) for a customized strategy consultation.